Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Haemonetics Corp (HAE)

Haemonetics Corp (HAE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,938,526
  • Shares Outstanding, K 50,683
  • Annual Sales, $ 967,580 K
  • Annual Income, $ 55,020 K
  • 60-Month Beta 0.77
  • Price/Sales 6.16
  • Price/Cash Flow 25.38
  • Price/Book 10.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.76
  • Number of Estimates 4
  • High Estimate 0.82
  • Low Estimate 0.74
  • Prior Year 0.63
  • Growth Rate Est. (year over year) +20.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.15 +1.75%
on 12/12/19
123.52 -5.14%
on 11/20/19
-3.51 (-2.91%)
since 11/12/19
3-Month
115.15 +1.75%
on 12/12/19
132.73 -11.72%
on 09/20/19
-8.71 (-6.92%)
since 09/12/19
52-Week
80.24 +46.03%
on 04/18/19
140.36 -16.52%
on 08/19/19
+13.37 (+12.88%)
since 12/12/18

Most Recent Stories

More News
Intersect ENT (XENT) Grows on Innovation Despite Cost Woes

The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.

XENT : 21.48 (+2.73%)
NUVA : 73.85 (+0.09%)
RMD : 152.25 (+1.18%)
HAE : 117.17 (-0.32%)
Walgreens Extends Deal to Form GPO With Retail Giant Kroger

Per Walgreens (WBA), its alliance with Kroger will lead to supply chain efficiencies, capitalizing on their joint resources.

RMD : 152.25 (+1.18%)
HAE : 117.17 (-0.32%)
NUVA : 73.85 (+0.09%)
WBA : 58.58 (+0.98%)
Here's Why You Should Hold on to Quest Diagnostics Stock Now

Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.

HAE : 117.17 (-0.32%)
NUVA : 73.85 (+0.09%)
RMD : 152.25 (+1.18%)
DGX : 105.32 (+0.56%)
Here's Why You Should Add Omnicell to Your Portfolio Now

Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.

OMCL : 80.92 (-0.91%)
HAE : 117.17 (-0.32%)
RMD : 152.25 (+1.18%)
NUVA : 73.85 (+0.09%)
Haemonetics Opens New Corporate Headquarters In Downtown Boston

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today opened its new global headquarters...

HAE : 117.17 (-0.32%)
CVS Health Rides on Aetna Prospects, Strong Selling Season

CVS Health's (CVS) 2020 PBM selling season is approaching closure and the 2021 selling season is ongoing.

RMD : 152.25 (+1.18%)
HAE : 117.17 (-0.32%)
CVS : 74.26 (+1.24%)
EYE : 31.76 (+3.69%)
Omnicell-Huron Sign a Pact for Outcome-Based Expert Services

Omnicell (OMCL) partners Huron to provide customers with committed expertise.

OMCL : 80.92 (-0.91%)
RMD : 152.25 (+1.18%)
HAE : 117.17 (-0.32%)
EYE : 31.76 (+3.69%)
Bruker Launches Luxendo TruLive3D Imager in Mass Spectrometry

Bruker's (BRKR) Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environment.

BRKR : 49.58 (+0.08%)
RMD : 152.25 (+1.18%)
HAE : 117.17 (-0.32%)
EYE : 31.76 (+3.69%)
Globus Medical Hits 52-Week High: What's Driving the Stock?

Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.

GMED : 57.79 (+1.58%)
RMD : 152.25 (+1.18%)
HAE : 117.17 (-0.32%)
EYE : 31.76 (+3.69%)
Omnicell (OMCL) Partners With Kit Check to Offer Bluesight

This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.

OMCL : 80.92 (-0.91%)
NUVA : 73.85 (+0.09%)
RMD : 152.25 (+1.18%)
HAE : 117.17 (-0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade HAE with:

Business Summary

Haemonetics Corporation is a Global Leader in Blood Management Solutions. Their comprehensive portfolio of devices, information management, consulting services offers blood management solutions for each facet of the blood supply chain from plasma blood collectors to hospitals. They believe that through...

See More

Key Turning Points

2nd Resistance Point 120.94
1st Resistance Point 119.06
Last Price 117.17
1st Support Level 115.22
2nd Support Level 113.26

See More

52-Week High 140.36
Fibonacci 61.8% 117.39
Last Price 117.17
Fibonacci 50% 110.30
Fibonacci 38.2% 103.20
52-Week Low 80.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar